Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 9/20 | 0.42 |
| ▸ | SRC | P12931 | 3/20 | 0.41 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 3/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.37 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30167709 | 1.00 | TTK (0.42) | TTKSRCPTK6AURKAFLT3 | |
| SCHEMBL30167898 | 0.89 | TTK (0.42) | TTKPTK6AURKAMAPKAPK5AURKB | |
| SCHEMBL24105244 | 0.89 | TTK (0.42) | TTKPTK6AURKAMAPKAPK5AURKB | |
| SCHEMBL25174076 | 0.86 | CYP11B1 (0.43) | TTKSRCAURKAFLT3AURKB | |
| SCHEMBL30168171 | 0.85 | EIF2AK4 (0.46) | TTKSRCPTK6AURKAFLT3 | |
| SCHEMBL24104677 | 0.84 | SRC (0.44) | TTKSRCPTK6AURKAFLT3 | |
| Hydrochloric Acid SCHEMBL30168143 | 0.84 | EIF2AK4 (0.45) | TTKSRCPTK6AURKAFLT3 | |
| SCHEMBL22160298 | 0.84 | TTK (0.48) | TTKSRCPTK6AURKAMAPKAPK5 | |
| SCHEMBL22123273 | 0.84 | TTK (0.50) | TTKSRCPTK6MAPKAPK5 | |
| SCHEMBL25173790 | 0.84 | TTK (0.48) | TTKSRCPTK6AURKAMAPKAPK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141403-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230141403-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| WO-2021249893-A1 | NOVEL IMIDAZO-PYRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141403-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | XDH, MYD88, IKZF3 | TTK 4157/4885SRC 2189/4885PTK6 2213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.